Search

Search Results

• PLASMA CELL LEUKEMIA UPDATE ON IMMUNOPHENOTYPE, MOLECULAR CHARACTERISTICS, AND THERAPY. The second part of plasma cell neoplasms with spreading in the blood and tissues Plasma Cell Leukemia

  Giuseppe G.M. Leone, Ugo Testa

  e2025080

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.080

  1369

  PDF: 377

  Html: 134

• Ixazomib-associated skin exfoliation

  Yali Zhang, Long Zhao, Yuancheng Guo, bei liu

  e2022045

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.045

  869

  PDF: 552

  HTML: 213

• COVID-19 post hematopoietic cell transplant, a report of 11 cases from a single center.

  Afadil Adam

  e2020070

  2020-08-29

  https://doi.org/10.4084/mjhid.2020.070

  1730

  PDF: 1136

  HTML: 295

• Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy

  Antonella Vaccarino, Irene Dogliotti, Fabio Marletto, Andrea Demarchi, Mario Bazzan

  e2016050

  2016-10-20

  https://doi.org/10.4084/mjhid.2016.050

  2819

  PDF: 772

  HTML: 1281

  Blood Count trend before and during lenalidomide treatment: 176

  Light micrograph of bone marrow biopsy of a patient with PV and 5q deletion: 198

• RECENT ADVANCES IN THE 5Q- SYNDROME

  Andrea Pellagatti, Jacqueline Boultwood

  e2015037

  2015-05-20

  https://doi.org/10.4084/mjhid.2015.037

  2815

  PDF: 1839

  HTML: 3687

  Pellagatti Fig 1: 222

  Pellagatti Fig. 2: 216

• THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

  Paul Richardson, Jacob Laubach, Anuj Mahindra, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Noopur Raje, Nikhil Munshi, Kenneth Anderson

  e2010009

  2010-05-03

  https://doi.org/10.4084/mjhid.2010.009

  1123

  PDF: 725

  HTML: 621

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1679

  PDF: 658

  HTML: 2437